Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
April 14 2023 - 7:50AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April, 2023
Commission File Number 000-29962
Kazia Therapeutics Limited
(Translation of registrants name into English)
Three
International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☑ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On April 13, 2023, Kazia Therapeutics Limited (the Company) received a letter from the Listing Qualifications Staff
(the Staff) of The Nasdaq Stock Market LLC (Nasdaq) confirming the Company has regained compliance with Nasdaqs minimum bid price requirement under Listing Rule 5550(a)(2). The Company previously received
notification on December 9, 2022, that its American Depository Shares (ADSs) were not in compliance with Nasdaqs minimum bid price requirement, having closed at a price below US$ 1.00 per share for thirty consecutive business days. In the
letter received on April 13, 2023, the Staff determined that, during the ten consecutive business days from March 29, 2023 to April 12, 2023, the closing bid price of the companys ADSs has been at $1.00 per share or greater and
accordingly, the Company has regained compliance with Listing Rule 5550(a)(2). The Company also issued an ASX announcement titled, Kazia Regains Compliance with Nasdaq Minimum Bid Price Requirement. A copy of this release is attached
hereto as Exhibit 99.1 and is incorporated herein by reference.
The Company hereby incorporates by reference the information
contained herein, including Exhibit 99.1, into the Companys registration statement on Form F-3 (File No. 333-259224).
EXHIBIT LIST
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
Kazia Therapeutics Limited (Registrant) |
|
/s/ Karen Krumeich |
Karen Krumeich |
Chief Financial Officer |
|
Date: 14 April 2023 |
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024